Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries

IMPORTANCE: Idelalisib (IDEL) is approved as monotherapy in relapsed follicular lymphoma (FL) and with rituximab (IDEL+R) for relapsed chronic lymphocytic leukemia (CLL). Toxic effects can be severe and treatment-limiting. Outcomes in a real-world population are not yet characterized. OBJECTIVE: We...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Oncol
Päätekijät: Bird, Steven T., Tian, Fang, Flowers, Natasha, Przepiorka, Donna, Wang, Rongrong, Jung, Tae-Hyun, Kessler, Zebulin, Woods, Corinne, Kim, Bo, Miller, Barry W., Wernecke, Michael, Kim, Clara, McKean, Stephen, Gelperin, Kate, MaCurdy, Thomas E., Kelman, Jeffrey A., Graham, David J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2019
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990831/
https://ncbi.nlm.nih.gov/pubmed/31855259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.3994
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia